For more substantial or chronic conditions (e.g., tendon injuries or longstanding inflammation), treatments may last 46 weeks to see full or peak effects, and some individuals may require longer cycles for maximal benefit
It is not intended to diagnose, prevent or treat any medical condition
Marketed by Meitheal Pharmaceuticals Inc., this product is identified by NDC 71288-300 and is authorized under FDA application ANDA214316
This removes guesswork and ensures consistency throughout your protocol
Other conditions such as diabetes, autoimmune disorders, infections, and mechanical nerve compression can also produce similar symptoms
The SURMOUNT-5 trial directly compared tirzepatide to semaglutide, demonstrating superior weight loss outcomes at equivalent therapeutic doses